Atlas Trials

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Clinical trial NCT06551116 · RECRUITING

Trial details

NCT number
NCT06551116
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Study type
OBSERVATIONAL
HER2-positive Metastatic Breast Cancer
Start date
2024-10-10
Primary completion
2029-09-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.